

## Chiesi Group 2022 Aggregated Scoring Methodology

### Aggregated Scoring Methodology

Chiesi Farmaceutici S.p.A and all of its subsidiaries were required to be assessed in the B Impact Assessment and undergo a review by B Lab staff. Chiesi Farmaceutici S.p.A and its subsidiaries were divided into 19 assessments, and the overall score was calculated using an employee headcount-based weighted average. The 19 assessments are as follows:

- Chiesi Group<sup>1</sup>
- Chiesi S.A.S<sup>2</sup>
- Chiesi Farmaceutica LTDA
- Chiesi Pharmaceuticals GmbH<sup>3</sup>
- Chiesi Espana S.A.U
- Chiesi USA Inc<sup>4</sup>
- Chiesi Pharmaceuticals B.V.
- Chiesi Limited<sup>5</sup>
- OOO Chiesi Pharmaceuticals
- Chiesi Mexico
- Chiesi Poland
- Chiesi SA/NV
- Chiesi Australia PTY LTD<sup>6</sup>
- Chiesi GmbH
- Chiesi İlaç Ticaret A.Ş.
- Chiesi Pharma AB
- CHIESI ΕΛΛΑΣ AEBE
- Chiesi Pharmaceutica (Shanghai) Co.Ltd
- Chiesi Pakistan

The Group scored an overall 103.8 out of 200 total available points. The minimum verified score required for B Corp Certification is 80.

Learn more about the [B Impact Assessment](#).

---

<sup>1</sup> Assessment for Chiesi Group includes Marco Antonetto (IT), Chiesi Italia SpA Societa Benefit, Chiesi Farmaceutici SpA Societa Benefit

<sup>2</sup> Assessment for Chiesi S.A.S (FR) includes Chiesi S.A.S, NhCo Nutrition S.A.S

<sup>3</sup> Assessment for Chiesi Pharmaceuticals GmbH (DE) includes Chiesi Pharmaceuticals GmbH (DE), Chiesi Slovakia S.r.o. (SK), Chiesi Slovenija D.o.o. (SI), Chiesi Bulgaria Ltd (BG), Chiesi CZ S.r.o. (CZ), Chiesi Hungary Kft. (HU), Chiesi România S.r.l. (RO), Chiesi SA

<sup>4</sup> Assessment for Chiesi USA Inc (USA) includes Chiesi USA Inc Benefit Corporation (USA), Chiesi Canada Corporation (CA), Cornerstone Biopharma Inc, EKR Holdings Inc, EKR Therapeutics Inc

<sup>5</sup> Assessment for Chiesi Limited (UK) includes Chiesi Healthcare Limited (UK), Unikeris Limited, Chiesi Limited

<sup>6</sup> Assessment for Chiesi Australia includes Chiesi New Zealand Limited (NZ), Chiesi Australia Pty Limited (AUS)

**Chiesi Group**  
**2022 Aggregated Scoring Methodology**

## **Subsidiaries**

As the B Corporation Certification is a company-level certification, the assessment of a Parent Company is required to include its subsidiaries in which it owns >50% of the shares and has controlling interest. Depending on the operations of the certifying company, Parent Companies may roll up their subsidiaries into a single assessment or assess separately.

Regardless of whether a Certified Parent Company's subsidiaries are assessed together or separately, only distinct subsidiaries that B Lab has determined independently meet the performance requirement for certification are eligible to use the Certified B Corporation logo and refer to themselves as Certified B Corporations.

The overall scores for individual company assessments, which were used by B Lab to determine the overall score of Chiesi Group, are listed below:

<b>Company name</b>	<b>Overall BIA Score</b>
Chiesi Group	112.1
Chiesi S.A.S	100.6
Chiesi Farmaceutica LTDA	102.8
Chiesi Pharmaceuticals GmbH	86.1
Chiesi Espana S.A.U	109.9
Chiesi USA Inc	97.4
Chiesi Pharmaceuticals B.V.	97.7
Chiesi Limited	113.5
OOO Chiesi Pharmaceuticals	94.1
Chiesi Mexico	88.7
Chiesi Poland	93.3
Chiesi SA/NV	97.8
Chiesi Australia PTY LTD	77.5
Chiesi GmbH	95.9
Chiesi İlaç Ticaret A.Ş.	94.8
Chiesi Pharma AB	108.3
CHIESI ΕΜΑΣ ΑΕΒΕ	103.8
Chiesi Pharmaceutica (Shanghai) Co.Ltd	104.7
Chiesi Pakistan	86.4